| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Fukuoka, Fukuoka 812, Japan
1 To whom requests for reprints should be addressed.
To elucidate the mechanism of the synergistic cytotoxicity of 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum(II) (CDDP), we studied the interaction of these agents using a human squamous carcinoma cell line (HST-1). Exposure to 5-FU for 24 h and to CDDP for 1 h produced a 50% inhibitory concentration of 1.0 µg/ml (7.7 µm) and 2.5 µg/ml (8.3 µm), respectively. The cytotoxic action of CDDP was augmented, and a greater than additive effect was observed when the cells were exposed to 5-FU (1.0 µg/ml; 7.7 µm) for 24 h before the CDDP treatment. This synergistic activity was maximal when the interval between 5-FU and CDDP exceeded 24 h. In contrast, the cytotoxicity of CDDP was attenuated when it preceded the exposure to 5-FU. Thymidine did not alter the 5-FU-CDDP interaction. Evaluation of the kinetics of the removal of DNA interstrand cross-links, measured by alkaline elution, showed a significant reduction of this removal in the cells exposed to 5-FU followed by CDDP with a drug-free interval of 48 h, as compared with cells exposed to CDDP alone, or to 5-FU immediately followed by CDDP, although no differences were found in the formation of DNA interstrand cross-links by CDDP among these cells. No significant differences in the accumulation of intracellular platinum were detected by atomic absorption spectrophotometry. These findings suggest that 5-FU modulates the repair of platinum-DNA adducts, thereby potentiating the antitumor activity of CDDP.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 6/16/92. Accepted 9/24/92.
This article has been cited by other articles:
![]() |
E. BABA, H. FUJISHIMA, H. KUSABA, T. ESAKI, H. ARIYAMA, K. KATO, R. TANAKA, K. MITSUGI, Y. SHIBATA, M. HARADA, et al. Phase I Study of the Sequential Administration of S-1 and Cisplatin for Metastatic Gastric Cancer Anticancer Res, May 1, 2009; 29(5): 1727 - 1732. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Galetta, A. Cesario, S. Margaritora, V. Porziella, G. Macis, R. M. D'Angelillo, L. Trodella, S. Sterzi, and P. Granone Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach Ann. Thorac. Surg., December 1, 2003; 76(6): 1802 - 1809. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nishiyama, W. Yamamoto, J.-S. Park, R. Okamoto, H. Hanaoka, H. Takano, N. Saito, M. Matsukawa, T. Shirasaka, and M. Kurihara Low-Dose Cisplatin and 5-Fluorouracil in Combination CanRepress Increased Gene Expression of Cellular Resistance Determinants to Themselves Clin. Cancer Res., September 1, 1999; 5(9): 2620 - 2628. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zeghari-Squalli, E. Raymond, E. Cvitkovic, and F. Goldwasser Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin Clin. Cancer Res., May 1, 1999; 5(5): 1189 - 1196. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |